300318 博晖创新
已收盘 01-13 15:00:00
资讯
新帖
简况
博晖创新（300318）披露控股孙公司联合获得药物临床试验批准通知书，1月13日股价上涨3.15%
证券之星 · 01-13 22:15
博晖创新（300318）披露控股孙公司联合获得药物临床试验批准通知书，1月13日股价上涨3.15%
博晖创新最新公告：控股孙公司联合获得冻干人用狂犬病疫苗临床试验批准通知书
证券之星 · 01-13 18:30
博晖创新最新公告：控股孙公司联合获得冻干人用狂犬病疫苗临床试验批准通知书
股市必读：博晖创新（300318）12月26日董秘有最新回复
证券之星 · 2025-12-29
股市必读：博晖创新（300318）12月26日董秘有最新回复
博晖创新：公司股东人数可关注公司披露的定期报告
证券日报 · 2025-12-26
博晖创新：公司股东人数可关注公司披露的定期报告
博晖创新最新公告：控股子公司获得静注人免疫球蛋白临床试验批准通知书
证券之星 · 2025-12-23
博晖创新最新公告：控股子公司获得静注人免疫球蛋白临床试验批准通知书
博晖创新(300318.SZ)子公司人凝血因子Ⅷ获得药品注册证书
智通财经 · 2025-12-23
博晖创新(300318.SZ)子公司人凝血因子Ⅷ获得药品注册证书
博晖创新：流感检测产品近期出现不同程度增长
证券之星 · 2025-12-05
博晖创新：流感检测产品近期出现不同程度增长
博晖创新（300318）披露控股孙公司疫苗获批临床试验，11月13日股价上涨13.47%
证券之星 · 2025-11-13
博晖创新（300318）披露控股孙公司疫苗获批临床试验，11月13日股价上涨13.47%
博晖创新：补选非独立董事
证券日报 · 2025-11-13
博晖创新：补选非独立董事
异动快报：博晖创新（300318）11月12日9点45分触及涨停板
证券之星 · 2025-11-12
异动快报：博晖创新（300318）11月12日9点45分触及涨停板
博晖创新（300318）披露控股孙公司联合获得药物临床试验批准通知书，11月11日股价上涨1.01%
证券之星 · 2025-11-11
博晖创新（300318）披露控股孙公司联合获得药物临床试验批准通知书，11月11日股价上涨1.01%
博晖创新最新公告：控股孙公司联合获得冻干b型流感嗜血杆菌结合疫苗临床试验批准通知书
证券之星 · 2025-11-11
博晖创新最新公告：控股孙公司联合获得冻干b型流感嗜血杆菌结合疫苗临床试验批准通知书
博晖创新（300318）披露2025年三季度报告，10月30日股价下跌1.05%
证券之星 · 2025-10-30
博晖创新（300318）披露2025年三季度报告，10月30日股价下跌1.05%
博晖创新(300318.SZ)发布前三季度业绩，归母净亏损3361.52万元
智通财经 · 2025-10-29
博晖创新(300318.SZ)发布前三季度业绩，归母净亏损3361.52万元
图解博晖创新三季报：第三季度单季净利润同比下降281.18%
证券之星 · 2025-10-29
图解博晖创新三季报：第三季度单季净利润同比下降281.18%
股市必读：博晖创新（300318）9月26日董秘有最新回复
证券之星 · 2025-09-29
股市必读：博晖创新（300318）9月26日董秘有最新回复
博晖创新：狂犬疫苗复产将带来新增长
证券之星 · 2025-09-26
博晖创新：狂犬疫苗复产将带来新增长
股市必读：博晖创新（300318）9月19日董秘有最新回复
证券之星 · 2025-09-22
股市必读：博晖创新（300318）9月19日董秘有最新回复
股市必读：博晖创新（300318）9月5日董秘有最新回复
证券之星 · 2025-09-08
股市必读：博晖创新（300318）9月5日董秘有最新回复
股市必读：博晖创新中报 - 第二季度单季净利润同比下降288.33%
证券之星 · 2025-08-29
股市必读：博晖创新中报 - 第二季度单季净利润同比下降288.33%
加载更多
公司概况
公司名称：
北京博晖创新生物技术集团股份有限公司
所属行业：
专用设备制造业
上市日期：
2012-05-23
主营业务：
北京博晖创新生物技术集团股份有限公司的主营业务是体外诊断产品的研发、生产与销售。公司的主要产品是检验仪器及检测试剂。
发行价格：
15.00
{"stockData":{"symbol":"300318","market":"SZ","secType":"STK","nameCN":"博晖创新","latestPrice":6.87,"timestamp":1768287804000,"preClose":6.66,"halted":0,"volume":43893661,"delay":0,"changeRate":0.0315,"floatShares":799000000,"shares":817000000,"eps":-0.0589,"marketStatus":"已收盘","change":0.21,"latestTime":"01-13 15:00:00","open":6.72,"high":7.09,"low":6.61,"amount":303000000,"amplitude":0.0721,"askPrice":6.87,"askSize":37,"bidPrice":6.86,"bidSize":1147,"shortable":0,"etf":0,"ttmEps":-0.0589,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":5,"adr":0,"adjPreClose":6.66,"symbolType":"stock","openAndCloseTimeList":[[1768267800000,1768275000000],[1768280400000,1768287600000]],"highLimit":7.33,"lowLimit":5.99,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":816900495,"isCdr":false,"pbRate":4.04,"roa":"--","roe":"--","epsLYR":0.0113,"committee":0.658656,"marketValue":5612000000,"turnoverRate":0.055,"status":0,"floatMarketCap":5486000000},"requestUrl":"/m/hq/s/300318","defaultTab":"news","newsList":[{"id":"2603680129","title":"博晖创新（300318）披露控股孙公司联合获得药物临床试验批准通知书，1月13日股价上涨3.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603680129","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603680129?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:15","pubTimestamp":1768313718,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，博晖创新报收于6.87元，较前一交易日上涨3.15%，最新总市值为56.12亿元。该股当日开盘6.72元，最高7.09元，最低6.61元，成交额达3.03亿元，换手率为5.5%。近日，博晖创新发布公告称，公司控股孙公司博晖生物制药股份有限公司与北京百晖生物科技有限公司联合申报的冻干人用狂犬病疫苗获得国家药品监督管理局签发的《药物临床试验批准通知书》，同意开展用于预防狂犬病的临床试验。本次获批不会对公司近期业绩产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300042216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300318","BK0251","BK0048"],"gpt_icon":0},{"id":"2603750049","title":"博晖创新最新公告：控股孙公司联合获得冻干人用狂犬病疫苗临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2603750049","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603750049?lang=zh_cn&edition=full","pubTime":"2026-01-13 18:30","pubTimestamp":1768300258,"startTime":"0","endTime":"0","summary":"博晖创新公告称，公司控股孙公司博晖生物制药股份有限公司与北京百晖生物科技有限公司联合申报的冻干人用狂犬病疫苗获得国家药品监督管理局出具的《药物临床试验批准通知书》，同意开展临床试验。该疫苗通过纯化的狂犬病毒抗原刺激机体产生免疫反应，用于预防狂犬病。目前国内已上市的人用狂犬病疫苗厂家包括成都康华生物制品股份有限公司、北京民海生物科技有限公司。该批准不会对公司近期业绩产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300031950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300318","BK0048","BK0251","159646","BK0028"],"gpt_icon":0},{"id":"2595527660","title":"股市必读：博晖创新（300318）12月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2595527660","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595527660?lang=zh_cn&edition=full","pubTime":"2025-12-29 03:26","pubTimestamp":1766949971,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，博晖创新报收于6.42元，上涨0.31%，换手率1.47%，成交量11.71万手，成交额7495.85万元。董秘最新回复投资者： 董秘你好！公司股东人数可关注公司披露的定期报告。当日关注点来自交易信息汇总：12月26日主力资金净流入399.27万元，显示主力对博晖创新股票的积极介入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900001217.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0251","BK0048","300318"],"gpt_icon":0},{"id":"2594291672","title":"博晖创新：公司股东人数可关注公司披露的定期报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2594291672","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594291672?lang=zh_cn&edition=full","pubTime":"2025-12-26 21:33","pubTimestamp":1766755980,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月26日，博晖创新在互动平台回答投资者提问时表示，公司股东人数可关注公司披露的定期报告。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-26/doc-inhecwez7847979.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-26/doc-inhecwez7847979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0251","BK0048","300318"],"gpt_icon":0},{"id":"2593968304","title":"博晖创新最新公告：控股子公司获得静注人免疫球蛋白临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593968304","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593968304?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:43","pubTimestamp":1766482999,"startTime":"0","endTime":"0","summary":"博晖创新公告称，公司控股子公司广东卫伦生物制药有限公司申报的静注人免疫球蛋白获得国家药品监督管理局出具的《药物临床试验批准通知书》，同意开展临床试验。广东卫伦需按批件内容进行临床研究并经国家药品监督管理局审批通过后方可上市。该药物已在国内外上市销售，国内有多家血液制品企业的静注人免疫球蛋白上市销售。该批准通知书是研发的阶段性成果，不会对公司近期业绩产生重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300028252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300318","BK0251","BK0028","BK0048"],"gpt_icon":0},{"id":"2593469460","title":"博晖创新(300318.SZ)子公司人凝血因子Ⅷ获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593469460","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593469460?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:11","pubTimestamp":1766477492,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博晖创新(300318.SZ)发布公告，公司控股子公司博晖生物制药(河北)有限公司(以下简称“河北博晖”)研发的药品人凝血因子Ⅷ于近日收到国家药品监督管理局核准签发的《药品注册证书》。本品对缺乏人凝血因子Ⅷ所致的凝血机能障碍具有纠正作用，主要用于防治血友病A和获得性凝血因子Ⅷ缺乏而致的出血症状及这类病人的手术出血治疗。本次获得“人凝血因子VIII”《药品注册证书》，是对公司产品的进一步补充，丰富了公司产品线，对河北博晖提高血浆利用效率具有重要的意义。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博晖创新(300318.SZ)子公司人凝血因子Ⅷ获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300318","BK0028","BK0048","BK0251"],"gpt_icon":0},{"id":"2589673188","title":"博晖创新：流感检测产品近期出现不同程度增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2589673188","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589673188?lang=zh_cn&edition=full","pubTime":"2025-12-05 16:15","pubTimestamp":1764922527,"startTime":"0","endTime":"0","summary":"证券之星消息，博晖创新(300318)12月05日在投资者关系平台上答复投资者关心的问题。投资者提问：公司流感检测相关业务近期是否增量明显？博晖创新回复：尊敬的投资者，您好！受益于市场需求与产品布局完善的双重驱动，公司流感检测相关产品近期出现不同程度的增长，具体经营数据请以公司在指定信息披露媒体发布的公告为准。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500020723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0048","BK0028","300318","BK0251"],"gpt_icon":0},{"id":"2583595793","title":"博晖创新（300318）披露控股孙公司疫苗获批临床试验，11月13日股价上涨13.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583595793","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583595793?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:08","pubTimestamp":1763042900,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，博晖创新报收于8.17元，较前一交易日上涨13.47%，最新总市值为66.74亿元。该股当日开盘7.62元，最高8.63元，最低7.41元，成交额达11.16亿元，换手率为17.65%。公司于近日发布关于股票交易异常波动的公告，称其控股孙公司博晖生物制药股份有限公司与北京百晖生物科技有限公司联合申报的冻干b型流感嗜血杆菌结合疫苗已获国家药品监督管理局批准开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","159646","300318","BK0048","BK0028"],"gpt_icon":0},{"id":"2583666599","title":"博晖创新：补选非独立董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2583666599","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583666599?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:06","pubTimestamp":1763042760,"startTime":"0","endTime":"0","summary":"证券日报网讯 11月13日晚间，博晖创新发布公告称，公司于2025年11月13日召开第八届董事会第十五次会议，审议通过《关于补选非独立董事的议案》，同意提名刁举鹏先生为公司第八届董事会非独立董事候选人，并提交公司股东大会进行选举。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-13/doc-infxhqmr2290809.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-13/doc-infxhqmr2290809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0251","BK0028","BK0048","300318"],"gpt_icon":0},{"id":"2582121413","title":"异动快报：博晖创新（300318）11月12日9点45分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2582121413","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582121413?lang=zh_cn&edition=full","pubTime":"2025-11-12 09:45","pubTimestamp":1762911926,"startTime":"0","endTime":"0","summary":"证券之星11月12日盘中消息，9点45分博晖创新触及涨停板。目前价格6.49，上涨8.17%。其所属行业生物制品目前上涨。领涨股为博晖创新。该股为猴痘概念，体外诊断，医疗器械概念热股，当日猴痘概念概念上涨1.19%，体外诊断概念上涨0.74%，医疗器械概念上涨0.65%。11月11日的资金流向数据方面，主力资金净流出417.83万元，占总成交额9.5%，游资资金净流出31.27万元，占总成交额0.71%，散户资金净流入449.09万元，占总成交额10.22%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200008331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300318","BK0048","BK0028"],"gpt_icon":0},{"id":"2582367090","title":"博晖创新（300318）披露控股孙公司联合获得药物临床试验批准通知书，11月11日股价上涨1.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582367090","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582367090?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:38","pubTimestamp":1762871907,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，博晖创新报收于6.0元，较前一交易日上涨1.01%，最新总市值为49.01亿元。公司近日发布公告称，其控股孙公司博晖生物制药股份有限公司与北京百晖生物科技有限公司联合申报的冻干b型流感嗜血杆菌结合疫苗，已获国家药品监督管理局签发的《药物临床试验批准通知书》，同意开展临床试验。目前该疫苗尚需开展临床试验并经监管部门批准后方可上市。本次获批不会对公司近期业绩产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100041117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300318","BK0028","BK0251","BK0048"],"gpt_icon":0},{"id":"2582354049","title":"博晖创新最新公告：控股孙公司联合获得冻干b型流感嗜血杆菌结合疫苗临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2582354049","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582354049?lang=zh_cn&edition=full","pubTime":"2025-11-11 17:30","pubTimestamp":1762853457,"startTime":"0","endTime":"0","summary":"博晖创新公告称，公司控股孙公司博晖生物制药股份有限公司与北京百晖生物科技有限公司联合申报的冻干b型流感嗜血杆菌结合疫苗获得国家药品监督管理局出具的《药物临床试验批准通知书》，同意开展临床试验。该疫苗主要用于预防由b型流感嗜血杆菌引起的侵袭性感染。此次获得临床试验批准通知书是研发的阶段性成果，不会对公司近期业绩产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100028492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0048","BK0028","300318","BK0251","159646"],"gpt_icon":0},{"id":"2579116786","title":"博晖创新（300318）披露2025年三季度报告，10月30日股价下跌1.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579116786","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579116786?lang=zh_cn&edition=full","pubTime":"2025-10-30 18:06","pubTimestamp":1761818790,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘，博晖创新报收于5.64元，较前一交易日下跌1.05%，最新总市值为46.07亿元。近日，博晖创新发布《2025年第三季度报告》，披露了公司前三季度主要财务数据。报告显示，2025年第三季度公司实现营业收入224,795,115.32元，同比增长41.22%；但归属于上市公司股东的净利润为-14,926,965.32元，同比减少281.18%。股东信息方面，截至报告期末，公司普通股股东总数为28,173户。前十大股东中，杜江涛持股39.03%，为公司第一大股东；郝虹、梅迎军、杜江虹等分别位列其后。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000035814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0251","300318","BK0048"],"gpt_icon":0},{"id":"2579900506","title":"博晖创新(300318.SZ)发布前三季度业绩，归母净亏损3361.52万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579900506","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579900506?lang=zh_cn&edition=full","pubTime":"2025-10-29 22:45","pubTimestamp":1761749110,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博晖创新(300318.SZ)发布2025年三季度报告，该公司前三季度营业收入为6.29亿元，同比减少2.68%。归属于上市公司股东的净亏损为3361.52万元。归属于上市公司股东的扣除非经常性损益的净亏损为1873万元。基本每股亏损为0.0411元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1362288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"博晖创新(300318.SZ)发布前三季度业绩，归母净亏损3361.52万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300318","BK0251","BK0048","BK0028"],"gpt_icon":0},{"id":"2579970653","title":"图解博晖创新三季报：第三季度单季净利润同比下降281.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579970653","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579970653?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:34","pubTimestamp":1761737676,"startTime":"0","endTime":"0","summary":"证券之星消息，博晖创新2025年三季报显示，前三季度公司主营收入6.29亿元，同比下降2.68%；归母净利润-3361.52万元，同比下降241.73%；扣非净利润-1873.0万元，同比下降219.63%；其中2025年第三季度，公司单季度主营收入2.25亿元，同比上升41.22%；单季度归母净利润-1492.7万元，同比下降281.18%；单季度扣非净利润86.7万元，同比上升108.12%；负债率47.1%，投资收益-10.3万元，财务费用2315.48万元，毛利率39.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900040374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300318"],"gpt_icon":0},{"id":"2571290378","title":"股市必读：博晖创新（300318）9月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2571290378","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571290378?lang=zh_cn&edition=full","pubTime":"2025-09-29 03:09","pubTimestamp":1759086553,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘，博晖创新报收于5.58元，下跌0.36%，换手率0.57%，成交量4.58万手，成交额2557.04万元。董秘最新回复投资者： 尊敬的董秘：停产4年的廊坊博晖狂犬疫苗5月获批生产，8月终于看到有批签了，能否介绍一下廊坊博晖的疫苗批签对3季度的业绩有何影响？当日关注点来自交易信息汇总：9月26日主力资金净流出233.62万元，显示主力小幅减持动向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092900001191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0048","300318","BK0028","BK0251"],"gpt_icon":0},{"id":"2570070957","title":"博晖创新：狂犬疫苗复产将带来新增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2570070957","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570070957?lang=zh_cn&edition=full","pubTime":"2025-09-26 15:54","pubTimestamp":1758873246,"startTime":"0","endTime":"0","summary":"证券之星消息，博晖创新09月26日在投资者关系平台上答复投资者关心的问题。廊坊博晖人用狂犬病疫苗的正式复产和批签预计将为公司带来新的收入增长点，随着市场推广和销售渠道拓展，有望增加公司的销售收入；同时，也有助于提升公司在疫苗市场的竞争力和品牌影响力，为后续业务发展奠定更坚实基础 。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092600022932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300318","159646","BK0028","BK0048","BK0251"],"gpt_icon":0},{"id":"2569220442","title":"股市必读：博晖创新（300318）9月19日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2569220442","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569220442?lang=zh_cn&edition=full","pubTime":"2025-09-22 03:35","pubTimestamp":1758483316,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘，博晖创新报收于5.7元，下跌1.38%，换手率0.88%，成交量7.05万手，成交额4025.61万元。董秘最新回复投资者： 尊敬的董秘您好，请问公司增发事宜，进展如何？相关事项如有动向将严格履行相关的流程并进行披露，请以公司在指定信息披露媒体发布的公告为准。当日关注点来自交易信息汇总：9月19日主力资金净流出414.87万元，显示主力小幅减持动向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200001157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300318","BK0048","BK0028"],"gpt_icon":0},{"id":"2565522766","title":"股市必读：博晖创新（300318）9月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2565522766","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565522766?lang=zh_cn&edition=full","pubTime":"2025-09-08 04:33","pubTimestamp":1757277190,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘，博晖创新报收于5.86元，上涨0.69%，换手率0.99%，成交量7.93万手，成交额4593.83万元。博晖生物制药（云南）有限公司根据新产品研发进度适时启动人纤维蛋白原、人凝血酶等产品配套生产线建设，目前产线建设基本完成并顺利进入试产测试，验证相关产品的工艺情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090800001162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300318","BK0048","BK0028"],"gpt_icon":0},{"id":"2563610400","title":"股市必读：博晖创新中报 - 第二季度单季净利润同比下降288.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563610400","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563610400?lang=zh_cn&edition=full","pubTime":"2025-08-29 05:23","pubTimestamp":1756416194,"startTime":"0","endTime":"0","summary":"截至2025年8月28日收盘，博晖创新报收于5.99元，下跌3.23%，换手率2.72%，成交量21.73万手，成交额1.3亿元。当日关注点来自交易信息汇总：8月28日主力资金净流出1011.61万元，游资资金净流入1359.51万元。来自业绩披露要点：2025年中报显示公司归母净利润为-1868.82万元，同比下降167.63%。股本股东变化股东户数变动近日博晖创新披露，截至2025年6月30日公司股东户数为3.11万户，较3月31日增加958.0户，增幅为3.18%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900004588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300318"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768343575972,"stockEarnings":[{"period":"1week","weight":0.0521},{"period":"1month","weight":0.0853},{"period":"3month","weight":0.2356},{"period":"6month","weight":0.101},{"period":"1year","weight":0.2938},{"period":"ytd","weight":0.0957}],"compareEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.0641},{"period":"3month","weight":0.0579},{"period":"6month","weight":0.1768},{"period":"1year","weight":0.3094},{"period":"ytd","weight":0.0428}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京博晖创新生物技术集团股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"28173人(较上一季度减少9.42%)","perCapita":"28344股","listingDate":"2012-05-23","address":"北京市昌平区生命园路9号院","registeredCapital":"81690万元","survey":" 北京博晖创新生物技术集团股份有限公司的主营业务是体外诊断产品的研发、生产与销售。公司的主要产品是检验仪器及检测试剂。","listedPrice":15},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博晖创新(300318)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博晖创新(300318)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博晖创新,300318,博晖创新股票,博晖创新股票老虎,博晖创新股票老虎国际,博晖创新行情,博晖创新股票行情,博晖创新股价,博晖创新股市,博晖创新股票价格,博晖创新股票交易,博晖创新股票购买,博晖创新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博晖创新(300318)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博晖创新(300318)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}